StockData
Galectin Therapeutics Inc logo

Galectin Therapeutics Inc (GALT) stock

GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.98+0.07 (+2.41%)

Close on Nov 18, 2026Market cap $300.53MP/E –Yield –

Galectin Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Galectin Therapeutics's pe ratio was 21.0× on Jan 31, 2019.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2019Jan 31, 201921.0×+6.1
2018Dec 31, 201814.9×–

More Galectin Therapeutics figures

See a number that looks wrong?